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Michel Salzet3, Isabelle Fournier3 & Young Mok Park1,2,4
Alzheimer’s disease (AD) is the most common form of dementia; however, mechanisms and 
biomarkers remain unclear. Here, we examined hippocampal CA4 and dentate gyrus subfields, which 
are less studied in the context of AD pathology, in post-mortem AD and control tissue to identify 
possible biomarkers. We performed mass spectrometry-based proteomic analysis combined with 
label-free quantification for identification of differentially expressed proteins. We identified 4,328 
proteins, of which 113 showed more than 2-fold higher or lower expression in AD hippocampi than 
in control tissues. Five proteins were identified as putative AD biomarkers (MDH2, PCLO, TRRAP, 
YWHAZ, and MUC19 isoform 5) and were cross-validated by immunoblotting, selected reaction 
monitoring, and MALDI imaging. We also used a bioinformatics approach to examine upstream 
signalling interactions of the 113 regulated proteins. Five upstream signalling (IGF1, BDNF, ZAP70, 
MYC, and cyclosporin A) factors showed novel interactions in AD hippocampi. Taken together, these 
results demonstrate a novel platform that may provide new strategies for the early detection of AD 
and thus its diagnosis.
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders, and its prevalence 
is estimated to increase two-fold in industrialized countries and by four-fold in developing countries 
over the next 20 years1. AD is characterized by a loss in connectivity in several brain fields in particular 
including the hippocampus. For instance, the density of synapses was significantly decreased in the outer 
molecular layer of the hippocampal dentate gyrus in AD2. Notably, the hippocampus plays a key role 
in the neurodegenerative events occurring in AD, since changes in this field are closely associated with 
memory loss and cognitive impairment3. Despite recent progress in understanding the mechanism of 
AD, our knowledge of the molecular details regarding this disease is still incomplete.
1Center for Cognition and Sociality, Institute for Basic Science, Daejeon 305-811, Republic of Korea. 2Mass 
Spectrometry Research Center, Korea Basic Science Institute, 804-1 Yangcheong-ri, Ochang-eup, Cheongwon-
gun, Chungbuk 363-883, Republic of Korea. 3Inserm U-1192, Laboratoire de Protéomique, Réponse Inflammatoire, 
Spectrométrie de Masse (PRISM), Université de Lille 1, Cité Scientifique, 59655 Villeneuve D’Ascq, France. 
4Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon 305-764, Republic 
of Korea. 5Department of Psychiatry, Morphological Brain Research Unit, University of Würzburg, Würzburg, 
Germany. 6Brain Bank Consultants, Amsterdam, The Netherlands. 7Institut de Neuropatologia, Servei Anatomia 
Patologica, IDIBELL-Hospital Universitari de Bellvitge, Universitat de Barcelona, Spain. 8School for Mental Health 
and Neuroscience, Department of Translational Neuroscience, Maastricht University, Maastricht, The Netherlands. 
*These authors contributed equally to this work. Correspondence and requests for materials should be addressed 
to I.F. (email: isabelle.fournier@univ-lille1.fr) or Y.M.P. (email: ympark@kbsi.re.kr)
Received: 19 December 2014
Accepted: 27 April 2015
Published: 10 June 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:11138 | DOi: 10.1038/srep11138
Many previous studies of AD have focused on the CA1 and CA3 fields of the hippocampus in various 
species4,5. By contrast, our laboratory has focused on these hippocampal fields less studied in the context 
of AD pathology. Notably, the DG plays a major role in age-related memory impairment but relatively 
little is known about the molecular mechanisms responsible for this memory loss6. Furthermore, patho-
logical changes in the DG, including granule cell loss and mossy fibre sprouting, are closely associated 
with status epilepticus7. Moreover, potential proteome-wide changes in the CA4 field of AD or their 
biological function remain unknown. In general, the lack of research on the DG and CA4 fields could 
in part be due to the lack of a clear distinction between the DG and CA4 in terms of their function and 
role in AD. This lack of clarity is why we specifically selected these fields from hippocampal tissues of 
AD patients and compared them to control samples.
Key initiating factors of AD include the accumulation of intraneuronal neurofibrillary tangles (NFTs) 
and the appearance of extracellular β -amyloid deposits8,9. One of the main histological findings in the 
brains of AD patients is the intracellular accumulation of NFTs10,11. Other histopathological features 
include the accumulation of extracellular senile plaques comprised of aggregated β -amyloid peptides. 
However, the molecular mechanisms associated with AD pathogenesis are not entirely understood. 
Moreover, some areas of the hippocampus are vulnerable to specific degenerative processes depending 
on their subfield and may differentially express proteins in specific stages of the disease. Intraneuronal 
neurofibrillary changes exhibit a characteristic pattern according to pathological stage of AD12. Therefore, 
in the current study, we focused on relatively early AD pathology, when accumulation of NFTs and neu-
ropil threads are first detected in the CA4/DG12 to elucidate mechanisms involved in the onset and devel-
opment of AD. To accomplish this, we used hippocampal specimens staged at AD Braak -IV and AD 
Braak -V. Using the differentially-expressed proteins identified from the CA4/DG field, we also examined 
protein-protein interaction networks associated with the mechanisms of AD through a bioinformatics 
approach. An examination of the signalling interaction networks associated with AD can provide insights 
into the molecular events mediating AD pathology. In addition, it can provide identifying potential new 
diagnostic or prognostic biomarkers.
Most previous studies that aimed to identify biomarkers for AD diagnosis have predominantly 
employed positron emission tomography (PET) and magnetic resonance imaging (MRI) approaches13. 
However, new tools have now been developed which are highly more sensitive and specific and are able 
to detect biomarkers relevant to disease progression and the signalling pathways underlying AD. Thus, in 
the current study, we combined mass spectrometry-based proteomic analysis with label-free quantification 
for identification and quantification of proteins from AD and control samples. We dissected the CA4 and 
DG fields from human hippocampal tissues and used one-dimensional liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) with subsequent database searches to identify peptides. Using this 
methodology, we identified previously unknown pathological mechanisms of AD. Additionally, the use 
of multiple high-throughput technologies enabled the detection of novel proteins and cellular signal-
ling pathways associated with AD pathology. Among the proteins identified, we targeted five regulated 
proteins (MDH2, PCLO, TRRAP, YWHAZ, and MUC19 isoform 5) and cross-validated them by using 
western blot analyses, selective reaction monitoring (SRM), and matrix-assisted laser desorption/ioni-
zation (MALDI) mass spectrometry imaging (MSI). Thus, we combined leading proteomic technologies 
for use as a diagnostic tool for the identification novel AD biomarkers and candidate drug targets. Our 
results provide valuable clinical information and can be utilized as a novel platform for the early diag-
nosis of AD.
Results
AD biomarker identification. To select meaningful proteins from total identified proteins in AD and 
control hippocampi, we performed a systematic data-mining strategy using an in-house protocol that 
involved four stages (Fig. 1). A total of 5,784 proteins from AD and control hippocampal tissues were 
extensively profiled by high-resolution nanoLC/MS throughout stage 1 (Fig.  1B). We identified 4,328 
unique proteins from five AD hippocampus samples (2,085) and five control samples (2,243) (Fig. 2A,B) 
using a minimum of one unique peptide and a protein FDR of ≤1%. Thereafter, we adopted a ratio 
cut-off of ≥1.8 and ≤0.56 and obtained 113 proteins (52 upregulated proteins and 61 downregulated 
proteins; stage 3) (Table  1) for the refinedverification set; stage 4 (Fig.  1B). Recently, our institution14 
identified 5,971 proteins in AD hippocampal tissues by off-gel fractionation, and profiled these proteins 
by using a high-resolution mass spectrometer with collision-induced dissociation and electron transfer 
dissociation. Fig. 2C shows the number of identified proteins in the CA4 and DG subfields and the entire 
hippocampus.
For our experiments, we selected only five hippocampi per group from the total specimens 
(Supplementary Information 1) since our criteria discriminated against each subfield of the hippocam-
pus. For this purpose, we first investigated hippocampal histology to identify the individual subfields 
(Fig. 3A) and coupled our observations to MALDI MSI.
Validation of proteomic profiling data. To the best of our knowledge, no previous studies have 
linked MUC19 isoform 5 with AD until now. Since there are no commercially available human MUC19 
isoform 5 antibodies and the sequence of the MUC19 oligomeric protein (isoform 5) is slightly different 
from the full sequence of Muc19 protein (Supplementary Information 2). We used MALDI MSI and 
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spectral counting to confirm that MUC19 isoform 5 was highly expressed specifically in AD hippocam-
pal tissues in contrary to controls (Fig.  3B,  C). We next performed western blot analyses to confirm 
the expression levels of four proteins (MDH2, PCLO, TRRAP, and YWHAZ, with β -actin as control) 
identified in the CA4 and DG field of AD hippocampal tissues. Notably, higher levels of MDH2, PCLO, 
and TRRAP were observed in AD tissue than in control hippocampal tissue (Fig. 4A); however, lower 
levels of YWHAZ were observed in control tissue. Furthermore, the western blot data for these proteins 
correlated well with the spectral counting data (Fig. 4B). We also confirmed expression of MDH2 using 
SRM. As shown in Fig.  4C, MDH2 expression was approximately two-fold higher in AD hippocampi 
than in control tissue.
We selected proteins to investigate according to differences in their potential function (Fig. 5A). These 
unique classifications were composed of several categories including microtubule-based movement, 
cell-projection morphogenesis, neuronal development, glycolysis, neuronal-projection morphogene-
sis, and others as listed. Interestingly, proteins that were classified into the glycolysis category (PKM2, 
PGAM1, ENO3, PGK1, and MDH2) were found to be upregulated in AD tissue. By contrast, proteins 
classified as being involved in microtubule-based movement and chromatin organization tended to be 
downregulated in AD tissue (Fig.  5A). A large proportion of the cellular components identified were 
cytoskeletal proteins (Fig. 5B). In AD tissue, proteins classified as nucleotide binding and purine ribo-
nucleotide binding proteins tended to be downregulated rather than upregulated by more than two-fold 
(Fig. 5C).
Upstream signalling interactions of proteins differentially expressed in AD patients. We 
used Ingenuity Pathway Analysis (IPA) to investigate the potential signalling interactions of the 113 
proteins that were expressed more than 2-fold higher or lower in AD hippocampi than in control tis-
sues. We determined the five most significantly annotated upstream regulators by using z-scores and 
p values (Table  2). These included two growth factors (IGF1, insulin-like growth factor 1; and BDNF, 
Figure 1. Strategy for identifying putative biomarkers of AD. (A) Experimental scheme for analysis 
of regulated proteins from post-mortem AD tissues using mass spectrometry-based proteomic analysis 
with label-free quantification. (B) Protein prioritization scheme for the selection of candidate proteins for 
verification.
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brain-derived neurotrophic factor), one kinase (ZAP-70 tyrosine-protein kinase), one transcriptional 
regulator (Myc proto-oncogene protein), and one biological drug (cyclosporin A). These factors mark-
edly increased or decreased z-scores. We identified a signalling network representative of the relationship 
between the activation and/or inhibition of upstream regulators with downstream regulated proteins 
(Fig. 6A). Through these tools, we also determined a protein interaction network for the potential role 
of our identified proteins in various neurological disorders (Fig. 6B).
Discussion
We employed nanoLC coupled with ESI-ion trap MS. Since nanoLC-based MS has the advantages of high 
spectral resolution and the ability to be used with a shotgun strategy, it can be utilized for identifying a 
large number of proteins in complex protein mixtures.
Using this approach, we identified 113 candidate molecules in tissue from patients with AD. Among 
these proteins, approximately 75% had a previously unknown relationship with AD; however, 60% of 
the 113 proteins had previously been reported to be associated directly or indirectly with the brain. To 
narrow down our investigation, we selected proteins that had previously been identified in neurological 
disorders, and validated our proteomic targets by employing western blot analysis and SRM, and MALDI 
MSI. SRM is particularly useful for validating candidate biomarker that require isotopically labelled 
standard but have no available antibodies15. Moreover, MALDI MSI has emerged as a powerful tool for 
molecular imaging of thin tissue sections and can provide information about the spatial distribution of 
proteins in tissue16,17. The AD-associated proteins that we chose to further investigate included PCLO, 
Figure 2. Venn diagrams summarizing proteins identified in human hippocampal tissue obtained from 
Alzheimer’s disease and control patients. (A) Overlap of proteins identified in all five control hippocampi, 
(B) Overlap of proteins identified in all five AD hippocampi, (C) Overlap of proteins identified by 
comparison between the CA4 and DG subfields and the entire hippocampus.
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Upregulaton proteins
IPI00470912 C2orf16* 9.0 12 7.53 0.00 n.a 0.00982 IPI01018212 PKM2 22.2 34 6.87 2.92 2.35 0.01708 
IPI00216864 PDZRN4* 9.5 16 5.28 0.00 n.a 0.00731 IPI00333696 HEATR5B 7.8 21 5.72 2.43 2.35 0.01892 
IPI00876841 ZSWIM8 * 4.6 9 4.23 0.25 16.72 0.01489 IPI00069084 TRRAP 2.3 18 3.73 1.64 2.28 0.01892 
IPI00219446 PEBP1* 28.6 10 3.30 0.24 13.96 0.00040 IPI00943735 ANKRD36 6.3 10 3.15 1.38 2.28 0.01892 
IPI00871535 SPTAN1 3.0 13 9.35 1.01 9.24 0.01892 IPI00642259 DST 2.1 29 12.91 5.72 2.26 0.01899 
IPI00964552 COL12A1* 5.4 28 6.88 0.97 7.08 0.00444 IPI00218474 ENO3 14.7 14 2.17 0.98 2.21 0.01892 
IPI00084828 STXBP1* 11.8 9 3.78 0.57 6.67 0.01588 IPI00549725 PGAM1 17.5 9 3.78 1.74 2.17 0.01892 
IPI00413144 C15orf42 6.2 10 8.22 1.27 6.48 0.01766 IPI00291006 MDH2 27.9 25 11.18 5.21 2.15 0.01892 
IPI01014674 MUC19* 31.6 11 10.22 1.89 5.41 0.01349 IPI00414123 CRMP1 10.9 6 0.99 0.46 2.14 0.02350 
IPI00954159 AHCTF1P1 6.0 20 8.06 1.52 5.31 0.01856 IPI00025363 GFAP 61.1 195 38.93 18.50 2.10 0.01856 
IPI00382470 HSP90AA1 7.2 8 5.18 1.01 5.11 0.01892 IPI00550232 XIRP2 3.6 18 6.33 3.09 2.05 0.01892 
IPI00169383 PGK1 14.9 4 3.22 0.67 4.79 0.01839 IPI00045512 HMCN1 3.2 30 6.90 3.39 2.04 0.01892 
IPI00879193 TTC28 5.1 13 6.89 1.46 4.73 0.01856 IPI00006091 DMD 3.3 9 5.55 2.73 2.03 0.01899 
IPI00007188 SLC25A5 18.6 5 1.00 0.22 4.57 0.01856 IPI00215715 CAMK2A 13.5 14 4.42 2.18 2.03 0.01892 
IPI00884904 AHNAK2 3.4 15 10.25 2.79 3.67 0.01892 IPI00930130 TUBB6 48.0 107 1.92 0.95 2.02 0.01892 
IPI01011955 MKI67 7.2 21 5.33 1.53 3.49 0.01892 IPI00419908 GPR179 4.9 9 4.24 2.10 2.02 0.02350 
IPI00218658 ITPR1 5.8 13 4.20 1.27 3.31 0.01856 IPI00171636 NAV1 5.8 10 3.76 1.92 1.95 0.01892 
IPI00328089 HIVEP3* 6.4 17 8.16 2.53 3.22 0.01203 IPI01015973 MUC16 8.6 233 7.47 3.87 1.93 0.01892 
IPI00413173 MKI67 3.4 10 10.05 3.52 2.85 0.01856 IPI00004233 MKI67 7.2 21 9.39 4.93 1.90 0.02167 
IPI00411656 PCLO* 3.2 26 16.37 5.81 2.82 0.01588 IPI00925013 MLL3* 12.5 26 8.01 4.25 1.89 0.01689 
IPI00740909 ALMS1 4.5 21 6.37 2.28 2.80 0.01856 IPI00218621 SON 7.6 98 7.24 3.86 1.87 0.02078 
IPI00398002 PLEC 4.1 28 7.85 3.00 2.61 0.01892 IPI00329573 COL12A1 7.2 30 5.12 2.79 1.84 0.01932 
IPI00789624 PCLO 6.7 40 13.14 5.08 2.59 0.01839 IPI00797574 BOD1L 5.9 23 11.54 6.38 1.81 0.01856 
IPI00749231 GPR98 3.5 17 3.19 1.24 2.58 0.01892 IPI00021907 MBP 32.2 41 5.19 2.88 1.80 0.02579 
IPI00289776 MYCBP2 4.2 18 13.60 5.49 2.48 0.01892  
IPI00169307 ARH-GAP21* 6.3 27 7.77 3.17 2.45 0.01489  
IPI00854820 PPRC1 6.6 14 2.86 1.18 2.42 0.01892  
IPI00215631 VCAN 4.0 21 4.29 1.79 2.39 0.01892  
Downregulation proteins
IPI00102752 RBM15 7.6 20 4.99 8.89 0.56 0.01892 IPI00788168 MAST4 3.5 8 1.23 3.12 0.39 0.01892 
IPI00014845 DNAH8 3.9 29 2.63 4.73 0.56 0.01892 IPI00908811 CKB 32.3 26 1.05 2.69 0.39 0.01892 
IPI00217051 NAV3 11.7 33 8.65 15.58 0.56 0.01892 IPI00006451 NSF 5.0 4 1.01 2.58 0.39 0.01892 
IPI00044608 PLIN4 17.2 30 7.38 13.38 0.55 0.01892 IPI00031411 FAT1 3.0 17 2.66 7.08 0.38 0.01892 
IPI00854629 OBSCN 2.3 33 3.83 6.97 0.55 0.01892 IPI00983524 MBP 58.6 59 0.62 1.76 0.35 0.01856 
IPI00221325 RANBP2 5.3 14 3.98 7.24 0.55 0.02154 IPI00445401 HUWE1* 5.6 27 2.39 6.99 0.34 0.01203 
IPI00868928 KIF26B 5.5 19 3.45 6.39 0.54 0.01892 IPI00257508 DPYSL2* 23.3 27 3.22 10.01 0.32 0.01203 
IPI01018628 UTY 11.6 24 5.10 9.47 0.54 0.01892 IPI00021263 YWHAZ* 17.0 12 0.84 2.65 0.32 0.01489 
IPI00018352 UCHL1 19.2 10 1.77 3.30 0.53 0.01892 IPI00479743 POTEE 14.1 40 0.82 2.75 0.30 0.01892 
IPI00815697 NAV2 12.0 31 2.12 4.00 0.53 0.02549 IPI01019113 TUBB 49.6 155 0.23 0.79 0.30 0.01756 
IPI00003935 HIST2H2BE 19.0 9 1.27 2.39 0.53 0.01892 IPI00006510 TUBB1 11.7 11 0.29 0.99 0.30 0.01892 
IPI00008161 ATP12A 5.9 12 0.77 1.46 0.53 0.01892 IPI01019105 UTY 4.7 10 1.29 4.57 0.28 0.01892 
IPI00018511 TUBB4Q 11.7 12 0.51 0.98 0.52 0.01977 IPI00478021 DNAH8* 4.0 29 2.06 7.68 0.27 0.01676 
IPI00952742 SHANK2 4.6 14 2.05 4.00 0.51 0.01892 IPI00217002 KIAA2018 7.2 11 1.48 5.65 0.26 0.01856 
IPI00297593 USP34 4.0 25 3.75 7.30 0.51 0.01892 IPI00853390 GPR112* 5.8 34 1.84 7.91 0.23 0.00982 
IPI00306457 FNDC1 9.4 10 2.74 5.42 0.51 0.01892 IPI00443415 MCC* 5.5 9 0.99 4.32 0.23 0.01203 
Continued
www.nature.com/scientificreports/
6Scientific RepoRts | 5:11138 | DOi: 10.1038/srep11138
which is associated with major depressive disorder (MDD); MDH2, which has been shown to regulate 
oxidative stress; and TRRAP, which plays an important role, together with Fe65, in AD.
A recent genome-wide association study on MDD identified a specific relationship with a 
non-synonymous polymorphism (rs2522833) of a gene encoding the presynaptic protein, piccolo 
(PCLO)18, which is localized to nerve terminals of both excitatory and inhibitory synapses in the CNS 
and influences Ca2+-dependent monoamine neurotransmitter release19. Bassoon and PCLO are critical 
regulators of presynaptic ubiquitination and degradation20. Surprisingly, in the current study we found 
that PCLO levels were higher and ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1) levels were 
lower in the hippocampus of AD in contrary to controls (Fig. 4A). UCHL1 is related to mono-ubiquitin 
recycling and thereby, sustaining protein degradation by the ubiquitin-proteasome system (UPS). In 
addition, the down-regulation of UCHL1 in AD is determined by induction of the NF-kB pathway and 
an Aβ mediated up-regulation of BACE1, by interfering with its lysosomal degradation21. Our data sug-
gest that PCLO and UCHL1 could be potential targets for new treatment development.
There were a number of protein changes that were not unexpected between AD and control tissue. 
One such protein, MDH, is involved in oxidative stress which is a process well known as one of the 
major causes of AD pathology22. During oxidative stress, MDH activity and MDH2 mRNA expression 
increased by 19% and 22%, respectively, in a mouse hippocampal cell line (HT22)23. According to our 
western blot data (Fig. 4A), MDH2 was more highly expressed in AD hippocampal tissues than in con-
trols. SRM verified that MDH2 expression was approximately two-fold greater in AD tissue (Fig.  4C), 
and this difference between tissues was also consistently observed with spectral counting.
Another protein of interest, TRRAP, is a well-known cofactor of histone acetyltransferase, which binds 
to Tip60 to repair double-stranded DNA breaks24. TRRAP also plays a key role in the regulation of Fe65, 
which is a binding partner of the β -amyloid precursor protein, APP, to activate histone H4 acetylation 
at DNA strand breaks25. Therefore, it was not surprising that TRRAP was more highly expressed in AD 
hippocampi than in controls (Fig. 4A).
The 14-3-3 zeta protein isoform 1 (YWHAZ) is associated with tau phosphorylation in NFTs, which 
is a characteristic neurohistological marker of AD26,27. In AD hippocampal tissues, low levels of YWHAZ 
have been previously reported27. Our current data, including the spectral counting and western blotting 
data, is consistent with this previous report in that we observed lower YWHAZ expression in AD hip-
pocampal tissue than in control tissue (Fig. 4A).
In contrast to the function of YWHAZ, UCHL1 was previously reported28 to play an important role 
in preventing neurofibrillary tangle formation by de-ubiquitination of phosphorylated tau. Interestingly, 
UCHL1 expression was downregulated in patients with AD (Table 1) compared with that of the controls. 
We propose that the low levels of UCHL1 expression may have affected AD patients’ ability to prevent 
NFT formation.
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IPI00019848 HCFC1 7.5 15 3.51 6.95 0.51 0.02078 IPI00956686 ATXN7* 15.6 11 0.88 4.54 0.19 0.01203 
IPI00914628 USP24 4.5 9 1.76 3.48 0.50 0.02135 IPI00157790 KIAA0368 4.2 7 0.99 5.17 0.19 0.01856 
IPI00026320 UBR5 5.1 15 6.07 12.42 0.49 0.01892 IPI00220717 RBM15* 7.6 20 1.03 5.64 0.18 0.00731 
IPI00215877 APC 7.6 41 3.85 7.89 0.49 0.01892 IPI00795015 SACS* 1.9 15 0.99 5.78 0.17 0.00731 
IPI00946001 ONECUT2 26.8 15 3.48 7.17 0.49 0.01891 IPI00738216 KIAA0947* 7.1 15 0.62 3.82 0.16 0.01203 
IPI00298994 TLN1 6.9 18 4.76 9.93 0.48 0.01856 IPI00642705 ARID1A* 7.7 25 1.33 8.27 0.16 0.00731 
IPI00914890 MAST4 3.3 8 1.17 2.47 0.47 0.02154 IPI01014270 APOB 4.6 21 1.33 9.55 0.14 0.01856 
IPI00788188 DYNC2H1 5.4 24 2.83 6.05 0.47 0.01892 IPI00740545 POTEI* 11.2 26 0.21 1.54 0.14 0.00507 
IPI00007750 TUBA4A 37.4 56 0.55 1.19 0.46 0.01856 IPI00790327 ATP1A3* 8.7 27 0.40 4.10 0.10 0.01489 
IPI00026272 HIST-1H2AE 21.8 6 0.76 1.67 0.46 0.01892 IPI00879810 SPTAN1 5.3 18 1.00 10.50 0.10 0.01892 
IPI00985241 MBP 67.5 59 1.00 2.21 0.45 0.01892 IPI00917728 NEB* 3.7 58 0.80 9.19 0.09 0.00549 
IPI00215628 VCAN 5.5 9 1.17 2.75 0.43 0.02109 IPI00871227 HMCN1* 3.1 15 0.29 4.56 0.06 0.01203 
IPI00643465 TACC2 3.2 7 1.17 2.76 0.42 0.01892 IPI00386035 FLG* 11.7 21 0.00 6.61 n.a 0.00731 
IPI00179298 HUWE1* 5.6 43 4.55 10.74 0.42 0.01708 IPI00012645 SPTBN2* 5.9 10 0.00 6.66 n.a 0.00741 
IPI00847978 FAT3 1.0 13 2.56 6.06 0.42 0.02078  
Table 1.  Upregulation and downregulation proteins list ( Ratio ≥ 1.80 or p-value < 0.05*), SI = spectral 
index Asterisks indicate proteins with ratios that were significantly different from 1 (one-sample t-test, 
p < 0.05*).
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Another protein involved in AD pathology, ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1), is 
well known as an important protein involved the regulation of Ca2+ homeostasis and apoptosis in AD. 
ITPR1 is localized to the endoplasmic reticulum and interacts with β -amyloid peptide; it is possible 
that this interaction could influence intracellular calcium homeostasis29, induce inactivate eNOS, and 
ultimately lead to apoptosis. Our data indicated that ITPR1 was approximately three-fold higher in the 
AD hippocampus than in control tissues.
Levels of dihydropyrimidinase-related protein 2 (DPYSL2; CRMP2), E3 ubiquitin-protein ligase 
(HUWE1), and sodium/potassium-transporting ATPase subunit alpha-3 (ATP1A3) were significantly 
lower in AD samples compared with controls. DPYSL2 has been implicated in neuronal growth, polarity, 
and guidance as well as in AD30. Further, chromosomal microduplication or mutation of HUWE1 has 
been associated with mental retardation31. ATP1A3 is known to be a Na+ /K+ transporter important in 
maintaining Na+ /K+ gradients in neurons32.
The neuron navigator protein family is also of interest. According to our results, neuron navigator 1 
was upregulated whereas neuron navigator 2 and 3 were downregulated in AD tissue (Table  1). These 
proteins are regulators of axon guidance and serve as targets for miRNA. Neuron navigator 1 is a novel 
microtubule-associated protein, which is involved in neuronal migration33, while neuron navigator 2 
plays a key role in axonal elongation and formation. It provides stability to growing neurites34. Shioya 
et al.35 recently reported that a lack of correlation between the mRNA and protein levels of neuron navi-
gator 3. Interestingly, a recent study showed that neuron navigator 3 is involved in tumour suppression36.
Notably, IGF1 modulates the hyperphosphorylation of tau through activation of kinases37–40. The cited 
study39 reported that increased IGF1 levels in middle age are associated with a high risk of AD at an 
older age. In addition, hyper-activation of IGF1-receptor signalling is an important risk factor for AD41. 
We also identified four regulated proteins (dystrophin, glial fibrillary acidic protein [GFAP], myelin 
basic protein [MBP], and antigen KI-67 [MKI67]), which were highly expressed in AD tissue and were 
associated with IGF1 upstream regulation. This IGF1-associated signalling interaction could contribute 
to the pathogenesis of AD. Another growth factor protein identified was BDNF, which is associated with 
energy homeostasis42 and plays a neuroprotective role in AD 43,44. Furthermore, decreased BDNF mRNA 
and protein levels are observed in tauopathies and neurodegenerative disease45. Interestingly, our results 
suggest that Myc may inhibit the activation of BDNF-associated upstream regulators (Fig. 6A). The Myc 
Figure 3. (A) Annotated optical image of a hippocampal section obtained from an Alzheimer’s disease 
patient stained with toluidine blue; Horn of Ammon (CA), dentate gryus (DG), and subiculum (S). (B) 
MUC19 isoform 5 is highly expressed in AD hippocampal tissues. MALDI imaging mass spectrometry 
(MSI) data (MUC19; m/z 11,135 ± 0.05%). (C) Spectral counting data for MUC19.
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oncogene family of proteins are upregulated46 and induce apoptosis47 in AD. We found that seven down-
stream proteins (heat shock protein HSP 90-alpha [HSP90AA1], [MBP], [MKI67], phosphoglycerate 
mutase 1 [PGAM1], phosphoglycerate kinase 1 [PGK1], pyruvate kinase PKM, and ADP/ATP translo-
case 2 [SLC25A5]) were upregulated in AD tissue and were upstream regulators of Myc. According to 
our data, activation of Myc may inhibit BDNF, which is known to play a neuroprotective role in AD. 
Tyrosine-protein kinase ZAP-70 (ZAP70; SRK), which regulates the adaptive immune response, was one 
of the kinase proteins identified. Here, we identified four downstream proteins (HSP90AA1, ITPR1, E3 
ubiquitin-protein ligase MYCBP2, and plectin [PLEC]) associated with the upstream regulator ZAP70. 
ITPR1 is particularly important for the activation of apoptosis pathways downstream from the ER via 
activation of various kinases48–50 (Fig. 6A). These data suggest that activated ZAP70 may induce neuronal 
Figure 4. Validation of proteins identified by nanoLC coupled with ESI ion-trap MS. (A) Western blot 
analysis of MDH2, PCLO, TRRAP, and YWHAZ. (B) Spectral counting of PCLO, TRRAP, and YWHAZ. (C) 
Comparison of individual protein amounts with the fragmentation ratio (endogenous light peak area/heavy 
standard peak area) in AD and control tissues as assessed by SRM.
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Figure 5. Analysis of regulated proteins using DAVID functional Gene Ontology. (A) Biological 
processes. (B) Cellular components. (C) Molecular functions (EASE score > 1.3, p < 0.05).
apoptosis through calcium-induced T lymphocyte apoptosis and/or immune response pathways. We also 
identified an inhibitor of upstream regulation, cyclosporin A (CsA), which is a biologic drug. CsA is 
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an immunosuppressive cyclic peptide that binds cyclophilin A51. In addition, CsA prevents neuronal 
death52,53 and β -amyloid-induced late-phase long-term potentiation deficits54. These data suggest that 
CsA may be a potential therapeutic agent for the treatment of AD by negatively regulating downstream 
proteins (GFAP, HSP90AA1, ITPR1, and MDH2). A number of proteins were also associated with neu-
rological disease pathways (Fig. 6B).
When dealing with human tissues, many variables must be taken into account that could poten-
tially influence study results including age, PMI, sex, and other factors. The post-mortem integrity of 
post-translational protein modifications is largely unknown; however, in an AD patient population, fac-
tors such as age, gender, and PMI, had no significant effect on neuronal nuclear diameter55. Additionally, 
rapid autopsy programs are not well established56,57. Even with these variables, human brain-based 
research is still required and will aid our understanding of disease pathology58. In particular, when con-
sidering recent findings related to pathological analyses of the CA4 and DG fields from patients with 
AD. Notably, our group was the first to provide a molecular study of the CA4 and DG subfields in AD12.
AD is classically diagnosed by neuropsychological testing combined with neuroimaging. Both meth-
ods are non-invasive; however, both approaches are also not very sensitive. One recent addition to the 
approaches adopted to clinically diagnose this debilitating disease is the use of biomarkers, including 
β -amyloid and tau, measured in the cerebral spinal fluid59,60. More specificity was introduced with the 
use of PET and Pittsburgh compound B, which can identify amyloid deposits. With our approach, dis-
ease diagnosis can be further improved, since proteomic changes can now be observed at high reso-
lution on a cellular level. Obviously, our method has the disadvantage of being invasive and can only 
be performed post-mortem, limiting most of our observations to the late stages of AD; however, we 
believe that this proteomic approach will be particularly useful for examining connectomics in AD in 
which amyloid-induced neurotoxicity induces a loss of connections between neurons, thereby initiating 
the neurodegenerative process. Consequently, the five putative AD biomarkers (MDH2, PCLO, TRRAP, 
YWHAZ, and MUC19) are not just potential biomarkers. Instead, together with the five upstream sig-
nalling factors (IGF1, BDNF, ZAP70, MYC, and cyclosporin A) they could help uncover the molecular 
mechanisms mediating AD or different neurodegenerative diseases.
Methods
Ethics statement and collection of human tissues. All experiments were approved by the local 
Ethic Committee in accordance with the Spanish and European legislation on this topic. Methods of 
collection for human brain tissues were performed in accordance with procedures that were approved 
by the Ethics Committee of the University of Barcelona.
Chemicals. All chemicals were of the highest purity obtainable. Water, formic acid, trifluoroacetic 
acid (TFA), acetonitrile (ACN), and methanol were purchased from Biosolve B. V. (Valkenswaard, the 
Netherlands). Ammonium bicarbonate, ethanol (EtOH), α -cyano-4-hydroxycinnamic acid, aniline 
(ANI), sinapinic acid (SA), and 1,1,1,3,3,3-hexafluoro-2-propanol reagents for Toluidine blue staining 
were purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France). Trypsin was purchased from 
Promega (Charbonnieres, France).
Human tissue. Control and AD hippocampal specimens were acquired from the Barcelona Brain 
Bank in Spain. Control hippocampi were obtained from donors who had no known history of neu-
rological or psychiatric disease. The inclusion criterion for AD tissue was a clinical diagnosis (AD-IV, 
AD-V). Once the tissue was received, it was immediately frozen and stored at –80 °C until further use. 
For this study, we used the following brain specimens: controls (age 55, 52, 63, 68, and 69 years with 
a post-mortem interval (PMI) of 9, 3, 6, 4, and 3 h, respectively), AD samples (age 79, 83, 75, 77, and 
Upstream
Regulator
Molecule
Type
Activation
z-score
p-value Target molecules
in regulated proteins
ZAP70 Kinase 2.000 4.12E–06 HSP90AA1, ITPR1, MY-CBP2, PLEC
IGF1 Growth factor 1.970 6.92E–03 DMD,GFAP, MBP, MKI67
BDNF Growth factor 1.953 8.33E–04 GFAP, HSP90AA1, ITPR1, MBP
MYC Transcription regulator 1.865 2.49E–03
HSP90AA1, MBP, MKI67, 
PGAM1, PGK1, PKM, 
SLC25A5
Cyclosporin A Biologic drug − 1.982 7.61E–03 GFAP, HSP90AA1, ITPR1, MDH2
Table 2.  Annotated upstream regulators listed according to z-scores and p values.
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56 years, with a PMI of 18, 15, 11, 20, and 7 h, respectively) (Supplementary Information 1). Tissues 
were acquired and stored by the Barcelona Brain Bank, who also obtained informed consent and ethics 
committee approval.
Tissue sample preparation. Ten-micrometre sections were obtained using a cryostat CM1510S 
(Leica Microsystems, Nanterre, France) and mounted onto indium-tin oxide (ITO)-coated conductive 
glass slides (Bruker Daltonics, Bremen, Germany). Sections were then vacuum-dried in a desiccator for 
10 min and placed in a series of 70% EtOH, 95% EtOH, and chloroform solutions for 30 s each with 
concomitant drying under vacuum for 5 min. Sections were then dried and stored under vacuum. After 
MALDI analysis, the matrix was removed from some sections by washing slides with 70% EtOH; these 
sections were then stained using toluidine blue.
Matrix deposition. For matrix deposition, an ionic matrix solution containing 10 mg/mL of SA 
and one equivalent of ANI in ACN/0.1% TFA (7:3, v/v) was prepared. The matrix was deposited on 
human hippocampal tissue sections with an automatic ImagePrep sprayer (Bruker Daltonics, Bremen, 
Germany), which creates an aerosol by vibrational vaporization and provides high-resolution images. SA/
ANI deposition was performed using a custom method composed of an initialization phase to deposit 
the first layer of matrix on the slide followed by phases enabling favourable co-crystallization of matrix 
crystals and analytes (by virtue of alternating cycles of partial and complete drying).
MALDI-TOF MSI. The MALDI matrix was applied using an ImagePrep device as described above. 
Protein imaging was then performed on an Ultraflex II MALDI-TOF/TOF instrument (Bruker Daltonics, 
Bremen, Germany) equipped with a smartbeam laser (Nd:YAG, 355 nm). Protein mass spectra were 
acquired in linear positive ion mode within a mass range of m/z 3,000–30,000. The distance between 
raster points was set to 80 μ m with a total of 500 laser shots accumulated at a 200-Hz repetition rate 
for each pixel. Spectra were processed by baseline correction and smoothed using FlexAnalysis 3.2 soft-
ware (Bruker Daltonics, Bremen, Germany). Image analysis and data visualization were performed with 
FlexImaging 2.1 software (Bruker Daltonics, Bremen, Germany). For statistical analysis, datasets obtained 
from FlexImaging were loaded into ClinProTools 2.2 software (Bruker Daltonics, Bremen, Germany) to 
conduct hierarchical clustering. Unsupervised clustering was selected with Euclidean as the distance 
method and Ward as the linkage method.
MALDI image normalization. Normalization of MALDI imaging data is not appropriate for single 
spectra, but instead requires the dataset as a whole. Here, we normalized data with the aim of equalizing 
the total ion count for all spectra to counter the effect of image ‘hot spots’. One example of a hot spot 
occurring is when a large matrix crystal had been hit directly by the laser beam, resulting in higher 
spectrum intensity at this point. However, normalization has the disadvantage of artificially increasing 
Figure 6. Features of proteomic signalling interactions. (A) Signalling network for the relationship 
between the activation and/or inhibition of upstream regulators with downstream regulated proteins 
(B) Interaction network for canonical neurological disease pathways including proteins that were up/
downregulated in AD tissue.
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the intensity of pure noise spectra. It is therefore possible to exclude noise spectra by defining a Ymean/
Ymax cutoff. Normalization was performed according to the following calculation:
=
+ + … +
Ymean
y y y
n
n1 22 2 2
y = y value at a point in the spectrumn = number of data points in the spectrumIf Ymean < threshold 
factor × maximum value of the y-axis, then the spectrum will be normalized.
Histological staining. For toluidine blue staining, tissue sections were removed from the SA/ANI 
matrix with 70% EtOH and dried; thereafter, sections were stained with toluidine blue for 1–2 min and 
washed in distilled water. After dehydration in a series of graded EtOH solutions, sections were placed 
in xylene, mounted, and examined by light microscopy61.
Micro tissue extraction. Human brain tissue sections (20-μ m thickness) were obtained using a 
cryostat CM1510S (Leica Microsystems, Nanterre, France) and mounted onto parafilm-covered slides. 
Micro-extraction was performed using microscopy to extract the CA4 and DG fields from AD and 
control hippocampal tissues.
NanoLC-ESI ion-trap MS and MS/MS. After micro tissue extraction, analyses were performed on 
an ion-trap mass spectrometer (Esquire 3000 plus, Bucker Daltonics) equipped with a ESI ion source and 
on-line coupled to a nanoLC system. An injection of 0.5 μ L of the digest was performed with a Switchos 
Autosampler (Dionex Corporation) and separation was performed on a C18 silica-bonded stationary 
phase (75 μ m internal diameter, 150 mm long, 3 μ m particle size, 100 Å pore size, Dionex). Samples 
were washed with 100% mobile phase A (95% water, 5% ACN, 0.1% formic acid) for 2 minutes at a flow 
rate of 10 μ L/min. Peptides were then eluted using a linear gradient of 1%/minute mobile phase B (80% 
ACN, 20% water, 0.08% formic acid) for 70 minutes at a flow rate of 0.2 μ L/min. The Esquire system 
was operated in a data-dependent MS/MS mode in which 1 MS full scan was followed by 1 MS/MS scan 
on the most-abundant peptide ion. Collision energy was set to 35%. Heated capillary temperature and 
electrospray voltage were 160 °C and 1.5 kV respectively62.
Protein identification using label-free quantification and statistical analysis. Raw MS data 
from patients with AD and controls were processed for protein identification using Mascot Daemon 
(v.2.3.2) with a peptide mass tolerance of 100 ppm and a fragment mass tolerance of ±0.8 Da at a false 
discovery rate (FDR) of 1% for both proteins and peptides. All peak lists were identified with the human 
International Protein Index (IPI) database (v3.87; containing 91,491 entries) with a decoy using the 
following parameters: enzyme: trypsin, missed cleavages: ≤2, fixed modification: carbamidomethyl (C), 
variable modifications: oxidation (M), and phosphorylation (S, T, Y). For relative protein quantification, 
the Mascot output file (csv format) was first imported into Microsoft Excel with additional filtering 
applied as follows: protein score ≥40, elimination of contaminants, and reversed sequences for each 
IPI name. A spectral index (SI) was calculated by summing all spectral counts using only unique pep-
tides. Second, spectral indices from respective IPI names were normalized to the number of total counts 
estimating the relative amount of varying IPI names within a relative sample. Third, the average ratio 
of normalized SI was calculated between control tissue and AD tissue. Finally, a Student’s t-test was 
performed for each IPI name (p <0.05). To control the FDR, the resulting p values were adjusted for 
multiple testing according to the method of Benjamini and Hochberg63 and compared with a significance 
level of alpha = 0.05. A protein was accepted as differentially expressed if it exhibited a ratio >1.8 AD or 
control tissue and an adjusted p value <0.05.
Gene annotation and upstream regulator analysis. Gene ontology annotation enrichment analy-
sis was performed using the DAVID Bioinformatics Resource (v6.7) developed by NIAID, at the National 
Institutes of Health. Ingenuity Pathway Analysis (IPA; Ingenuity Systems, http://www.ingenuity.com) was 
used to functionally annotate genes implicated in disease and search for common upstream regulators.
Western blotting. For western blot analyses, protein extracts containing either 15 μ g of AD 
or control lysate. Blots were then incubated overnight with primary antibodies [rabbit polyclonal 
anti-TRRAP (1:1000, Abcam), rabbit polyclonal anti-YWHAZ (1:1000, AbFrontier), mouse monoclonal 
anti-PCLO (1:1000, Abcam), mouse monoclonal anti-MDH2 (1:1000, Abcam), and mouse monoclo-
nal anti-β -actin (1:5000, Sigma)] diluted in 5% skimmed milk powder in Tris-buffered saline (TBS) at 
4 °C. Primary antibodies were incubated with peroxidase-conjugated anti-rabbit IgG (1:5000, Sigma) or 
peroxidase-conjugated anti-mouse I gG (1:5000, Sigma) secondary antibodies at RT. Antibody-reactive 
protein bands were visualized with an ECL detection reagent (GE Healthcare).
Optimization for peptide synthesis and SRM analysis in the MS instrument. To perform SRM 
measurements, isotopically-labelled peptides were optimized with Optimizer software (MassHunter 
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optimizer, version B. 0.3, Agilent, Palo Alto, CA, USA) to obtain the best analysis conditions for the 
triple quadrupole MS instrument. The optimization process selected fragment moieties from precursor 
ions and set the collision energy of fragment ions in each peptide. These samples were analysed with 
a nanoLC chip SRM/triple quadrupole MS, coupled with a 1200 Nano HPLC-chip microfluidic device 
(Agilent Technologies, Santa Clara, CA, USA). Samples (6 μ L; 1.5 μ g of protein) were injected via an 
autosampler and loaded onto the chip enrichment column, trapping 160 nL with a capillary pump, with 
a loading flow of 4 μ L/min using a mobile phase composed of 0.1% formic acid in water. A separation 
column (Zorbax C18, 75 μ m × 150 mm, 5 μ m) was used for peptide separation, setting the analytical 
flow rate to 400 nL/min. Mobile phase A consisted of 97% water/3% ACN/0.1% formic acid, and mobile 
phase B consisted of 90% ACN/10% water/0.1% formic acid. The capillary pump flow rate was set at 4 μ L/
min for loading and washing the samples, using a 100% water/0.1% formic acid mobile phase. The LC 
gradient used increasing concentrations of B with the total run time equalling 60 min. ESI was accom-
plished by applying a spray voltage of 1840 V. MS instrument settings included a drying gas flow rate of 
2.5 L/min, with a gas temperature of 325 °C, and an applied fragmentor voltage of 135 V(Supplementary 
Information 3).
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